IPSEN S.A. PORT. EO 1/ FR0010259150 /
| 09/11/2024 13:00:33 | Var. 0.00 | Volume | Denaro13:00:33 | Lettera13:00:33 | Capitalizzazione di mercato | Dividend Y. | Rapporto P/E |
|---|---|---|---|---|---|---|---|
| 109.80EUR | 0.00% | - Fatturato: - |
109.80Quantità in denaro: - | 111.10Quantità in lettera: - | 9.24 bill.EUR | 1.09% | 14.16 |
GlobeNewswire
26/07
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and K...
GlobeNewswire
25/07
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its ful...
GlobeNewswire
25/07
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for ...
GlobeNewswire
11/07
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug con...
GlobeNewswire
02/07
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroend...
GlobeNewswire
10/06
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primar...
GlobeNewswire
07/06
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell eng...
GlobeNewswire
05/06
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...
GlobeNewswire
24/04
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines...
GlobeNewswire
22/04
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological di...
GlobeNewswire
02/04
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid t...
GlobeNewswire
13/02
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreat...
GlobeNewswire
07/12/2023
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire
07/12/2023
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid...
GlobeNewswire
13/11/2023
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaki...
GlobeNewswire
26/10/2023
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidan...
GlobeNewswire
23/10/2023
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
GlobeNewswire
04/09/2023
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
GlobeNewswire
01/09/2023
Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
